Numerous clinical trials, spanning Early Phase 1 through Phase 3, evaluate bortezomib across a broad range of oncological and immunological conditions, including multiple myeloma, mantle cell lymphoma, non-small cell lung cancer, and immune thrombocytopenia. Sponsored by major academic institutions and pharmaceutical organizations, these studies currently encompass active recruiting, completed, active not recruiting, and terminated cohorts.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07428369 | WITHDRAWN | Multiple Myeloma (MM) |
Regeneron Pharmaceuticals |
2026-06-05 | PHASE2; PHASE3 |
| NCT07072585 | NOT_YET_RECRUITING | Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
Children's Oncology Group |
2026-08-28 | PHASE2; PHASE3 |
| NCT07793422 | NOT_YET_RECRUITING | Amyloid Light Chain (AL) Amyloidosis |
AbbVie |
2026-11-29 | PHASE3 |
| NCT07624513 | NOT_YET_RECRUITING | Multiple Myeloma |
Dana-Farber Cancer Institute |
2026-06-08 | PHASE3 |
| NCT05257083 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Stichting European Myeloma Network |
2023-10-10 | PHASE3 |
| NCT07285239 | RECRUITING | Multiple Myeloma |
PrECOG, LLC. |
2026-09 | PHASE3 |
| NCT05561387 | RECRUITING | Plasma Cell Myeloma |
SWOG Cancer Research Network |
2023-10-12 | PHASE3 |
| NCT07247097 | NOT_YET_RECRUITING | Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Transplant Ineligible; Newly Diagnosed Multiple Myeloma (NDMM) |
Massachusetts General Hospital |
2026-08-01 | PHASE2 |
| NCT07665450 | NOT_YET_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2026-09-22 | PHASE3 |
| NCT06577025 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2024-08-20 | PHASE2 |
| NCT06015750 | WITHDRAWN | Hypophosphatasia |
Alexion Pharmaceuticals, Inc. |
2026-07-29 | PHASE4 |
| NCT04240054 | RECRUITING | Multiple Myeloma |
Medical College of Wisconsin |
2021-11-02 | PHASE2 |
| NCT07464210 | NOT_YET_RECRUITING | Waldenstrom Macroglobulinemia |
Seoul National University Hospital |
2026-06-01 | PHASE2 |
| NCT07601100 | NOT_YET_RECRUITING | Newly Diagnosed Multiple Myeloma |
Dana-Farber Cancer Institute |
2026-09-03 | PHASE1; PHASE2 |
| NCT07623798 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Innovent Biologics (Suzhou) Co. Ltd. |
2026-06-05 | PHASE3 |
| NCT07614360 | NOT_YET_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2026-08-03 | PHASE2 |
| NCT07764978 | RECRUITING | Newly Diagnosed Multiple Myeloma |
AstraZeneca |
2026-06-26 | PHASE3 |
| NCT06636552 | RECRUITING | Primary Plasma Cell Leukemia |
Hellenic Society of Hematology |
2021-11-19 | PHASE2 |
| NCT07709715 | NOT_YET_RECRUITING | Light Chain (AL) Amyloidosis |
Nexcella Inc. |
2027-01 | PHASE3 |
| NCT05695508 | RECRUITING | Multiple Myeloma |
University of Heidelberg Medical Center |
2022-12-01 | PHASE2 |
| NCT03643276 | RECRUITING | Acute Lymphoblastic Leukemia, Pediatric |
Martin Schrappe |
2018-07-15 | PHASE3 |
| NCT07391657 | RECRUITING | Relapsed Refractory Multiple Myeloma |
AstraZeneca |
2026-02-23 | PHASE3 |
| NCT07045909 | RECRUITING | De Novo Multiple Myeloma; Anitocabtagene Autoleucel |
PETHEMA Foundation |
2025-06-30 | PHASE2 |
| NCT05137054 | RECRUITING | Multiple Myeloma |
Regeneron Pharmaceuticals |
2022-08-17 | PHASE1 |
| NCT03850366 | RECRUITING | Hematological Malignancy |
Henry Ford Health System |
2016-03-08 | PHASE2 |
| NCT04414475 | RECRUITING | Multiple Myeloma, Refractory |
Karyopharm Therapeutics Inc |
2020-07-01 | PHASE2 |
| NCT03590171 | RECRUITING | Acute Lymphoblastic Leukemia (ALL) |
Charite University, Berlin, Germany |
2017-09-01 | PHASE2 |
| NCT07008638 | RECRUITING | Acute Myeloid Leukemia; TP53 |
Masonic Cancer Center, University of Minnesota |
2025-07-07 | PHASE1; PHASE2 |
| NCT04775550 | ACTIVE_NOT_RECRUITING | High-risk Smoldering Multiple Myeloma; Multiple Myeloma |
Omar Nadeem, MD |
2021-03-08 | PHASE2 |
| NCT07388602 | RECRUITING | Amyloidosis |
Sinocelltech Ltd. |
2026-01-08 | PHASE3 |
| NCT06158841 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2024-05-19 | PHASE3 |
| NCT06142396 | RECRUITING | Multiple Myeloma; Renal Failure |
Augusta University |
2024-11-01 | EARLY_PHASE1 |
| NCT07018050 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-09-12 | PHASE2 |
| NCT07789522 | NOT_YET_RECRUITING | Multiple Myeloma (MM) |
Institute of Hematology & Blood Diseases Hospital, China |
2026-10-01 | PHASE2 |
| NCT06681922 | RECRUITING | Graft Vs Host Disease |
Northwell Health |
2024-09-23 | PHASE1; PHASE2 |
| NCT04790474 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse; Refractory Multiple Myeloma |
Tel-Aviv Sourasky Medical Center |
2021-03-25 | PHASE2 |
| NCT03136146 | RECRUITING | Recurrent Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Burkitt Leukemia; Recurrent Burkitt Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Acute Lymphoblastic Leukemia; Refractory Burkitt Leukemia; Refractory Burkitt Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Lymphoblastic Lymphoma |
M.D. Anderson Cancer Center |
2017-08-09 | PHASE2 |
| NCT05665140 | RECRUITING | Newly Diagnosed Multiple Myeloma |
University Hopsital Schleswig Holstein Campus Lübeck |
2023-02-03 | PHASE2; PHASE3 |
| NCT00572169 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Arkansas |
2006-11 | PHASE3 |
| NCT05470491 | RECRUITING | HIV; Hematologic Malignancies |
National Cancer Institute (NCI) |
2023-01-26 | PHASE1; PHASE2 |
| NCT06348147 | WITHDRAWN | Newly Diagnosed Multiple Myeloma; Multiple Myeloma; Autologous Stem Cell Transplantation |
UNC Lineberger Comprehensive Cancer Center |
2026-07 | PHASE2 |
| NCT03319667 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
Sanofi |
2017-12-07 | PHASE3 |
| NCT05558319 | RECRUITING | Newly Diagnosed Multiple Myeloma |
PETHEMA Foundation |
2022-11-10 | PHASE3 |
| NCT04166565 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Extramedullary Plasmacytoma |
Stichting European Myeloma Network |
2019-10-31 | PHASE2 |
| NCT04133636 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2019-11-07 | PHASE2 |
| NCT05736419 | RECRUITING | Sickle Cell Disease; Thalassemia, Beta; Thalassemia |
Memorial Sloan Kettering Cancer Center |
2023-02-09 | PHASE2 |
| NCT05519085 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Celgene |
2022-09-20 | PHASE3 |
| NCT03829371 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Turin, Italy |
2019-01-03 | PHASE4 |
| NCT05681260 | RECRUITING | T-cell Lymphoblastic Lymphoma |
Children's Cancer Group, China |
2023-02-06 | PHASE3 |
| NCT05514990 | ACTIVE_NOT_RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
University of Southern California |
2022-10-07 | PHASE1; PHASE2 |
| NCT02718833 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Massachusetts General Hospital |
2016-06-21 | PHASE2 |
| NCT03989414 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Celgene |
2019-09-30 | PHASE1; PHASE2 |
| NCT06505369 | RECRUITING | Multiple Myeloma |
North Estonia Medical Centre |
2024-06-19 | PHASE2 |
| NCT06083922 | RECRUITING | Multiple Myeloma; Monoclonal Gammopathy of Renal Significance |
Memorial Sloan Kettering Cancer Center |
2023-10-16 | PHASE2 |
| NCT03117751 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma |
St. Jude Children's Research Hospital |
2017-03-29 | PHASE2; PHASE3 |
| NCT05392946 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
Mayo Clinic |
2022-08-11 | PHASE1; PHASE2 |
| NCT06152575 | RECRUITING | Multiple Myeloma |
Pfizer |
2024-02-08 | PHASE3 |
| NCT05289167 | RECRUITING | Graft-versus-host Disease |
Northwell Health |
2022-03-13 | PHASE1; PHASE2 |
| NCT03589222 | ACTIVE_NOT_RECRUITING | Refractory Multiple Myeloma |
PETHEMA Foundation |
2018-07-15 | PHASE2 |
| NCT03697356 | UNKNOWN | Waldenström's Macroglobulinemia |
Kosin University Gospel Hospital |
2019-03-06 | PHASE2 |
| NCT02783625 | COMPLETED | Lymphoma; Relapsed/Refractory T-cell Lymphomas |
Memorial Sloan Kettering Cancer Center |
2016-05-23 | PHASE1 |
| NCT05776940 | UNKNOWN | Immunoglobulin Light-chain Amyloidosis |
Air Force Military Medical University, China |
2023-03-31 | PHASE3 |
| NCT05849610 | ACTIVE_NOT_RECRUITING | High-Risk de Novo Multiple Myeloma |
PETHEMA Foundation |
2023-09-21 | PHASE2 |
| NCT02719613 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2016-07-15 | PHASE2 |
| NCT03844360 | RECRUITING | Hematological Neoplasms |
Wei Zhao |
2016-01-31 | PHASE4 |
| NCT06771180 | NOT_YET_RECRUITING | Monoclonal Gammopathy of Renal Significance (MGRS) |
Peking University People's Hospital |
2025-01-15 | PHASE2 |
| NCT06418477 | RECRUITING | Monoclonal Gammopathy of Renal Significance |
Peking University People's Hospital |
2024-06-15 | PHASE2 |
| NCT03641456 | UNKNOWN | Myeloma; Newly Diagnosed; High Risk |
Sun Yat-sen University |
2020-09-25 | PHASE2 |
| NCT05895201 | WITHDRAWN | Bone Marrow Transplant Complications; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia, Adult; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia |
Indiana University |
2023-11 | PHASE1; PHASE2 |
| NCT06203145 | UNKNOWN | Multiple Myeloma; Renal Injury |
Peking University First Hospital |
2024-01-02 | |
| NCT05572515 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Janssen Research & Development, LLC |
2023-03-29 | PHASE3 |
| NCT04722146 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-03-12 | PHASE1 |
| NCT03188172 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2017-09-28 | PHASE2 |
| NCT05083169 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-10-14 | PHASE3 |
| NCT02211755 | COMPLETED | Neoplasms; Myelodysplastic Syndromes; Lymphomas |
National Cancer Institute (NCI) |
2014-10-06 | PHASE1 |
| NCT04626791 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
Academic and Community Cancer Research United |
2021-08-03 | PHASE2 |
| NCT04717700 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Ida Bruun Kristensen |
2021-08-18 | PHASE2 |
| NCT03942224 | UNKNOWN | Plasma Cell Myeloma |
Emory University |
2019-07-03 | PHASE2 |
| NCT05123131 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Cancer Trials Ireland |
2022-04-01 | PHASE2 |
| NCT04091126 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2019-12-18 | PHASE1 |
| NCT04504825 | ACTIVE_NOT_RECRUITING | AL Amyloidosis |
Alexion Pharmaceuticals, Inc. |
2020-08-25 | PHASE3 |
| NCT04570631 | TERMINATED | Multiple Myeloma |
AbbVie |
2020-11-05 | PHASE1 |
| NCT04802356 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
PETHEMA Foundation |
2021-04-07 | PHASE2 |
| NCT04131309 | COMPLETED | Light Chain (AL) Amyloidosis, Stage 3B |
Stichting European Myeloma Network |
2019-09-23 | PHASE2 |
| NCT06189833 | UNKNOWN | Multiple Myeloma |
Stichting European Myeloma Network |
2023-11-23 | PHASE2 |
| NCT05147493 | UNKNOWN | Multiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases |
Hellenic Society of Hematology |
2022-04 | PHASE2 |
| NCT03129828 | COMPLETED | Diffuse Large B Cell Lymphoma |
Prof. Dr. Clemens Schmitt |
2017-03-17 | PHASE1; PHASE2 |
| NCT04285268 | WITHDRAWN | High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements |
Rutgers, The State University of New Jersey |
2020-05-06 | PHASE2 |
| NCT04939844 | COMPLETED | Multiple Myeloma |
Oslo University Hospital |
2021-06-29 | PHASE2 |
| NCT04423367 | COMPLETED | Acquired Pure Red Cell Aplasia |
Institute of Hematology & Blood Diseases Hospital, China |
2020-09-13 | PHASE2 |
| NCT03737136 | COMPLETED | Antibody-mediated Rejection |
Shahid Beheshti University of Medical Sciences |
2019-11-01 | |
| NCT01919086 | COMPLETED | Multiple Myeloma (MM) |
Memorial Sloan Kettering Cancer Center |
2013-08-06 | PHASE2 |
| NCT04140162 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Michigan Rogel Cancer Center |
2020-10-05 | PHASE2 |
| NCT06868667 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2021-07-28 | PHASE3 |
| NCT04484623 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2020-10-01 | PHASE3 |
| NCT04352205 | TERMINATED | Plasma Cell Myeloma; Renal Failure |
Emory University |
2020-05-07 | PHASE2 |
| NCT05383547 | UNKNOWN | Bortezomib; Glomerulonephritis; MN; MPGN; FSGS; IgA Nephropathy |
Ruijin Hospital |
2022-08-02 | |
| NCT05564052 | COMPLETED | Lymphoma, Mantle-Cell |
Janssen Research & Development, LLC |
2022-12-06 | PHASE2 |
| NCT04304144 | COMPLETED | AL Amyloidosis |
Alexion Pharmaceuticals, Inc. |
2020-03-18 | PHASE2 |
| NCT04392648 | WITHDRAWN | Relapsed and/or Refractory Multiple Myeloma |
Teva Branded Pharmaceutical Products R&D LLC |
2020-06-24 | PHASE1 |
| NCT04151667 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2019-11-22 | PHASE2 |
| NCT04996160 | COMPLETED | Acute Lymphoblastic Leukemia, Pediatric; Relapsed Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia |
Tanja Andrea Gruber |
2021-07-09 | PHASE1 |
| NCT05293509 | WITHDRAWN | Stem Cell Transplantation |
M.D. Anderson Cancer Center |
2022-03-02 | PHASE2 |
| NCT05982756 | UNKNOWN | Bortezomib; Acute Myeloid Leukemia |
Zhongnan Hospital |
2020-01-01 | PHASE1 |
| NCT03710603 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Stichting European Myeloma Network |
2018-12-14 | PHASE3 |
| NCT03742297 | ACTIVE_NOT_RECRUITING | Newly Diagnosed Multiple Myeloma |
PETHEMA Foundation |
2018-10-22 | PHASE3 |
| NCT05599880 | Recruiting | Relapsed/Refractory Immune Thrombocytopenia |
Seoul National University Hospital |
2023-07-07 | Phase 2 |
| NCT05781425 | Recruiting | Chemotherapy-induced Peripheral Neuropathy |
Odense University Hospital|Aarhus University Hospital|Sygehus Lillebaelt|University of Southern Denmark |
2023-05-12 | -- |
| NCT03544281 | COMPLETED | Multiple Myeloma |
GlaxoSmithKline |
2018-09-20 | PHASE1; PHASE2 |
| NCT04612582 | UNKNOWN | Immunoglobulin Light-Chain Amyloidosis |
Guangdong Provincial People's Hospital |
2020-01-01 | PHASE4 |
| NCT03617484 | WITHDRAWN | Mantle Cell Lymphoma |
University of Michigan Rogel Cancer Center |
2020-07 | PHASE2 |
| NCT04776850 | WITHDRAWN | Beta Thalassemia Major; Sickle Beta 0 Thalassemia; Sickle Beta Plus Thalassemia; Sickle Beta Thalassemia; Sickle Cell Disease; Sickle Cell-SS Disease |
M.D. Anderson Cancer Center |
2020-12-29 | EARLY_PHASE1 |
| NCT03620903 | ACTIVE_NOT_RECRUITING | Waldenstrom Macroglobulinemia |
Christian Buske |
2019-09-11 | PHASE2 |
| NCT04258683 | WITHDRAWN | Multiple Myeloma |
Canadian Myeloma Research Group |
2021-02-17 | PHASE2 |
| NCT05383547 | Unknown status | Bortezomib|Glomerulonephritis|MN|MPGN|FSGS|IgA Nephropathy |
Ruijin Hospital |
2022-08-02 | Not Applicable |
| NCT04915248 | Recruiting | Plasmablastic Lymphoma |
Fondazione Italiana Linfomi - ETS|Janssen-Cilag S.p.A. |
2022-07-11 | Phase 2 |
| NCT04956302 | TERMINATED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Abdullah Khan |
2021-09-27 | PHASE1 |
| NCT02553460 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia |
St. Jude Children's Research Hospital |
2016-01-29 | PHASE1; PHASE2 |
| NCT02844322 | COMPLETED | Waldenström Macroglobulinemia |
Institute of Hematology & Blood Diseases Hospital, China |
2016-05 | PHASE4 |
| NCT02514382 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
University of Southern California |
2015-08-21 | PHASE1 |
| NCT02461888 | COMPLETED | Multiple Myeloma |
University of Leeds |
2015-12 | PHASE2 |
| NCT03130348 | WITHDRAWN | Amyloidosis; Immunoglobulin Light Chain Deposition |
Mayo Clinic |
2018-03-15 | PHASE2 |
| NCT04277845 | UNKNOWN | Multiple Myeloma |
Samsung Medical Center |
2020-08-06 | PHASE2 |
| NCT01208662 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Paul Richardson, MD |
2010-09 | PHASE3 |
| NCT02513186 | COMPLETED | Plasma Cell Myeloma |
Sanofi |
2015-09-30 | PHASE1 |
| NCT01554852 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2010-05 | PHASE3 |
| NCT04065789 | COMPLETED | Myeloma Multiple; Myeloma, Plasma-Cell; Myeloma-Multiple; Plasma Cell Myeloma |
Tel-Aviv Sourasky Medical Center |
2018-05-02 | PHASE2 |
| NCT01038388 | COMPLETED | Multiple Myeloma |
Emory University |
2010-01-15 | PHASE1 |
| NCT04656951 | Recruiting | Multiple Myeloma |
University of Cologne|Janssen-Cilag G.m.b.H |
2021-06-01 | Phase 2 |
| NCT03416374 | COMPLETED | Relapsed and/or Refractory Multiple Myeloma |
Takeda |
2018-02-18 | PHASE4 |
| NCT00720785 | COMPLETED | Chronic Myeloid Leukemia (CML); Pancreatic Ca; Colon/Rectal Ca; Multiple Myeloma; Carcinoma, Non-Small -Cell Lung |
National Heart, Lung, and Blood Institute (NHLBI) |
2008-08-01 | PHASE1 |
| NCT03051841 | UNKNOWN | Myeloma, Multiple |
Chong Kun Dang Pharmaceutical |
2017-01 | PHASE1 |
| NCT01913730 | COMPLETED | Multiple Myeloma |
European Myeloma Network B.V. |
2013-11 | PHASE2 |
| NCT02755597 | COMPLETED | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2016-07-11 | PHASE3 |
| NCT00492050 | ACTIVE_NOT_RECRUITING | Waldenstrom's Macroglobulinemia |
M.D. Anderson Cancer Center |
2006-08-02 | PHASE2 |
| NCT03401372 | COMPLETED | Amyloidosis; Systemic |
Jian Li |
2018-04-21 | |
| NCT01208766 | COMPLETED | Multiple Myeloma |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2011-01 | PHASE3 |
| NCT03345303 | UNKNOWN | Intrahepatic Cholangiocarcinoma |
Zhengang Yuan |
2017-01 | PHASE3 |
| NCT01267812 | COMPLETED | Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma |
City of Hope Medical Center |
2011-10-03 | PHASE2 |
| NCT00477412 | COMPLETED | Mantle Cell Lymphoma |
M.D. Anderson Cancer Center |
2007-04-03 | PHASE1; PHASE2 |
| NCT03136653 | COMPLETED | Multiple Myeloma in Relapse |
Molecular Partners AG |
2017-05-23 | PHASE1; PHASE2 |
| NCT02440464 | COMPLETED | Multiple Myeloma |
National Heart, Lung, and Blood Institute (NHLBI) |
2015-08 | PHASE2 |
| NCT01849783 | COMPLETED | Extramedullary Plasmacytoma; Isolated Plasmacytoma of Bone; Light Chain Deposition Disease; Primary Systemic Amyloidosis; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Margarida Magalhaes-Silverman |
2013-04-04 | PHASE2 |
| NCT03487133 | COMPLETED | Relapsed and/or Refractory Cutaneous T-cell Lymphoma |
Samsung Medical Center |
2017-09-19 | PHASE2 |
| NCT02541383 | COMPLETED | Multiple Myeloma |
Intergroupe Francophone du Myelome |
2015-09 | PHASE3 |
| NCT03412565 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2018-04-26 | PHASE2 |
| NCT03515200 | TERMINATED | Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission |
St. Jude Children's Research Hospital |
2018-04-20 | PHASE1 |
| NCT03217812 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2017-11-23 | PHASE3 |
| NCT02525172 | UNKNOWN | Pompe Disease |
National Taiwan University Hospital |
2015-08 | PHASE4 |
| NCT01453101 | COMPLETED | Multiple Myeloma |
Hackensack Meridian Health |
2010-06-09 | PHASE2 |
| NCT03701321 | WITHDRAWN | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
National Cancer Institute (NCI) |
2019-01-25 | PHASE1; PHASE2 |
| NCT02626481 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2015-12-28 | PHASE2 |
| NCT03110562 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2017-05-24 | PHASE3 |
| NCT03201965 | COMPLETED | Amyloidosis |
Janssen Research & Development, LLC |
2017-10-05 | PHASE3 |
| NCT01668719 | COMPLETED | DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma |
SWOG Cancer Research Network |
2012-11 | PHASE1; PHASE2 |
| NCT01216683 | COMPLETED | Lymphoma |
ECOG-ACRIN Cancer Research Group |
2011-02-09 | PHASE2 |
| NCT02605356 | WITHDRAWN | Multiple Myeloma |
Bayer |
2016-10 | PHASE1; PHASE2 |
| NCT02219178 | COMPLETED | Multiple Myeloma |
Cancer Trials Ireland |
2014-11 | PHASE2 |
| NCT02654990 | COMPLETED | Multiple Myeloma |
pharmaand GmbH |
2016-04-27 | PHASE2 |
| NCT03700229 | UNKNOWN | Acquired Hemophilia A |
Peking Union Medical College Hospital |
2018-10-10 | PHASE2 |
| NCT03234972 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2017-11-30 | PHASE3 |
| NCT02703779 | COMPLETED | Multiple Myeloma |
Siddhartha Ganguly |
2016-03 | PHASE2 |
| NCT01833143 | COMPLETED | Non-Small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2013-04-11 | PHASE2 |
| NCT02336815 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-05-26 | PHASE2 |
| NCT01497093 | COMPLETED | Multiple Myeloma |
Celgene |
2012-02-15 | PHASE1 |
| NCT01163357 | COMPLETED | Autologous Hematopoietic Stem Cell Transplant Recipient; Loss of Chromosome 17p; Plasma Cell Leukemia; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
City of Hope Medical Center |
2011-01-28 | PHASE1 |
| NCT01794507 | COMPLETED | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2012-11-19 | PHASE1 |
| NCT02658396 | WITHDRAWN | Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple Myeloma |
Dana-Farber Cancer Institute |
PHASE1 | |
| NCT03242460 | COMPLETED | Relapsed and/or refractorY Multiple Myeloma |
Kosin University Gospel Hospital |
2015-05-12 | PHASE2 |
| NCT02928029 | TERMINATED | Multiple Myeloma |
Bayer |
2017-02-10 | PHASE1; PHASE2 |
| NCT01805557 | COMPLETED | Diffuse Large B-cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent |
Fondazione Italiana Linfomi - ETS |
2013-02-04 | PHASE2; PHASE3 |
| NCT01965353 | COMPLETED | Multiple Myeloma in Relapse |
Dana-Farber Cancer Institute |
2013-10 | PHASE1 |
| NCT01440582 | COMPLETED | Myeloma |
M.D. Anderson Cancer Center |
2013-02-18 | PHASE1 |
| NCT02197221 | COMPLETED | Multiple Myeloma |
University Hospital, Toulouse |
2015-01 | PHASE3 |
| NCT01788020 | COMPLETED | Waldenström's Macroglobulinemia |
University of Ulm |
2013-11 | PHASE3 |
| NCT01965977 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Samsung Medical Center |
2015-04-08 | PHASE2 |
| NCT02559154 | UNKNOWN | Multiple Myeloma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2010-07 | PHASE4 |
| NCT02237261 | COMPLETED | Multiple Myeloma |
University Hospital Heidelberg |
2014-11 | PHASE2 |
| NCT02308280 | COMPLETED | Multiple Myeloma; High-Risk Cancer |
Maisonneuve-Rosemont Hospital |
2014-11 | PHASE2 |
| NCT02955810 | UNKNOWN | Multiple Myeloma |
National University of Ireland, Galway, Ireland |
2016-11 | PHASE1 |
| NCT02500251 | COMPLETED | Renal Transplant Rejection |
E. Steve Woodle |
2015-06 | PHASE1; PHASE2 |
| NCT01695941 | ACTIVE_NOT_RECRUITING | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma |
National Cancer Institute (NCI) |
2012-08-31 | PHASE1 |
| NCT02811978 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2016-09-27 | PHASE3 |
| NCT00967369 | COMPLETED | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2009-08-24 | PHASE2 |
| NCT02951819 | COMPLETED | Multiple Myeloma |
Janssen Scientific Affairs, LLC |
2016-11-09 | PHASE2 |
| NCT02497378 | COMPLETED | Multiple Myeloma |
Janssen Pharmaceutical K.K. |
2015-07-10 | PHASE1 |
| NCT01926899 | COMPLETED | Hematopoetic Stem Cell Transplant |
Indiana University |
2013-08-01 | PHASE1 |
| NCT02158702 | UNKNOWN | Multiple Myeloma; Relapse After Use of Lenalidomide and Bortezomib |
National University Hospital, Singapore |
2014-11 | PHASE2 |
| NCT02206425 | COMPLETED | Multiple Myeloma |
Oncotherapeutics |
2014-09 | PHASE1; PHASE2 |
| NCT02290431 | COMPLETED | Relapse/Refractory Multiple Myeloma |
Novartis Pharmaceuticals |
2014-12-16 | PHASE2 |
| NCT02195479 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2014-12-09 | PHASE3 |
| NCT02208037 | COMPLETED | Acute Leukemia; Chronic Myelogenous Leukemia; Myelodysplasia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Hodgkin's Lymphoma |
National Heart, Lung, and Blood Institute (NHLBI) |
2014-08 | PHASE2 |
| NCT02563340 | UNKNOWN | Kidney Transplantation |
First Affiliated Hospital, Sun Yat-Sen University |
2015-11 | PHASE1; PHASE2 |
| NCT01212952 | COMPLETED | Refractory Multiple Myeloma |
Mayo Clinic |
2011-09 | PHASE1; PHASE2 |
| NCT01460420 | COMPLETED | Hematologic Malignancies; Multiple Myeloma |
European Myeloma Network B.V. |
2011-11 | PHASE1; PHASE2 |
| NCT02489500 | TERMINATED | AL Amyloidosis |
Boston Medical Center |
2015-06 | PHASE3 |
| NCT01103778 | COMPLETED | Chronic Kidney Disease; IgA Nephropathy |
The Rogosin Institute |
2010-07 | PHASE4 |
| NCT03000634 | WITHDRAWN | Multiple Myeloma |
University of Arkansas |
2017-04-01 | PHASE2 |
| NCT01672736 | TERMINATED | Multiple Myeloma |
University Health Network, Toronto |
2012-09 | PHASE1; PHASE2 |
| NCT01696474 | COMPLETED | Refractory Cold Agglutinin Disease |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2012-12 | PHASE2 |
| NCT01842074 | UNKNOWN | Patients Awaiting a Living Kidney Donation |
Assistance Publique - Hôpitaux de Paris |
2013-03 | PHASE4 |
| NCT01592981 | COMPLETED | Waldenstrom's Macroglobulinaemia |
University College, London |
2013-01 | PHASE2 |
| NCT01109004 | COMPLETED | Multiple Myeloma |
National Heart, Lung, and Blood Institute (NHLBI) |
2010-05 | PHASE3 |
| NCT01470131 | TERMINATED | Multiple Myeloma |
AB Science |
2011-05 | PHASE3 |
| NCT02893111 | COMPLETED | Neuromyelitis Optica Spectrum Disorder |
Tianjin Medical University General Hospital |
2015-12 | PHASE2 |
| NCT01827137 | COMPLETED | Multiple Myeloma |
Sellas Life Sciences Group |
2013-04 | PHASE1; PHASE2 |
| NCT02336386 | UNKNOWN | Extramedullary Plasmacytoma |
Beijing Chao Yang Hospital |
2014-12 | PHASE3 |
| NCT01522872 | UNKNOWN | Multiple Myeloma |
Threshold Pharmaceuticals |
2012-02 | PHASE1; PHASE2 |
| NCT01534260 | COMPLETED | Acute Myeloid Leukemia |
Hamid Sayar |
2012-02-10 | PHASE1; PHASE2 |
| NCT02082405 | WITHDRAWN | Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Case Comprehensive Cancer Center |
2015-04 | PHASE2 |
| NCT02220608 | COMPLETED | Multiple Myeloma |
Washington University School of Medicine |
2015-02-20 | PHASE1 |
| NCT02188537 | COMPLETED | Myeloma |
Swiss Cancer Institute |
2014-12-02 | PHASE2 |
| NCT02481934 | COMPLETED | Multiple Myeloma |
Joaquín Martínez López, MD, PhD |
2013-03 | PHASE1 |
| NCT01420926 | COMPLETED | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Therapy-Related Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2011-11-16 | PHASE2 |
| NCT01273844 | COMPLETED | Amyloidosis |
Zhi-Hong Liu, M.D. |
2011-03-01 | |
| NCT00737529 | COMPLETED | Mantle Cell Lymphoma |
Celgene |
2008-12-22 | PHASE2 |
| NCT00923247 | TERMINATED | Medullary Thyroid Carcinoma |
National Cancer Institute (NCI) |
2009-02-19 | PHASE1; PHASE2 |
| NCT01435395 | COMPLETED | Glioblastoma Multiforme |
Emory University |
2011-12 | PHASE1 |
| NCT01860170 | COMPLETED | Hematological Malignancy |
Corewell Health West |
2012-04 | PHASE1; PHASE2 |
| NCT01359657 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2011-09 | PHASE1 |
| NCT01936090 | COMPLETED | DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2013-08 | PHASE1 |
| NCT01277016 | COMPLETED | AL Amyloidosis |
European Myeloma Network B.V. |
2011-01 | PHASE3 |
| NCT00644228 | ACTIVE_NOT_RECRUITING | DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma |
National Cancer Institute (NCI) |
2008-07-28 | PHASE3 |
| NCT00634179 | COMPLETED | Lymphoma, B-Cell; Follicular Lymphoma |
Emory University |
2008-02 | PHASE1; PHASE2 |
| NCT00422799 | COMPLETED | Waldenstrom's Macroglobulinemia |
Dana-Farber Cancer Institute |
2006-08-30 | PHASE2 |
| NCT01695330 | TERMINATED | Multiple Myeloma |
Oncotherapeutics |
2012-05 | PHASE2 |
| NCT01485835 | COMPLETED | Multiple Myeloma |
Emory University |
2012-01 | PHASE1 |
| NCT01208818 | COMPLETED | Chronic Renal Failure With Uremic Nephropathy |
Assistance Publique - Hôpitaux de Paris |
2011-06 | PHASE3 |
| NCT01971658 | COMPLETED | Multiple Myeloma |
Nantes University Hospital |
2013-10 | PHASE3 |
| NCT00931918 | COMPLETED | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) |
Millennium Pharmaceuticals, Inc. |
2009-10 | PHASE2 |
| NCT01023308 | COMPLETED | Multiple Myeloma |
Novartis Pharmaceuticals |
2009-12-21 | PHASE3 |
| NCT01142401 | COMPLETED | Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2010-05-26 | PHASE2 |
| NCT02268890 | COMPLETED | Multiple Myeloma |
Johnson & Johnson Taiwan Ltd |
2014-12 | PHASE4 |
| NCT00903734 | COMPLETED | Advanced Cancers |
M.D. Anderson Cancer Center |
2009-04 | PHASE1 |
| NCT01647165 | WITHDRAWN | Multiple Myeloma |
National Cancer Institute (NCI) |
2012-07-11 | PHASE2 |
| NCT01594242 | COMPLETED | Multiple Myeloma |
Abramson Cancer Center at Penn Medicine |
2012-07-10 | EARLY_PHASE1 |
| NCT01349595 | TERMINATED | Disorder of Transplanted Kidney |
Mark Stegall |
2011-12 | PHASE2 |
| NCT01090921 | COMPLETED | Multiple Myeloma |
Boston VA Research Institute, Inc. |
2007-05 | PHASE2 |
| NCT01873157 | COMPLETED | Late Rejection of Renal Transplant; Antibody-mediated Rejection |
Medical University of Vienna |
2013-12 | PHASE2 |
| NCT01075425 | COMPLETED | Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia |
Virginia Commonwealth University |
2010-05 | PHASE1 |
| NCT01495351 | COMPLETED | Multiple Myeloma |
AHS Cancer Control Alberta |
2011-10 | PHASE1 |
| NCT02037256 | COMPLETED | Adult Grade III Lymphomatoid Granulomatosis; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Small Lymphocytic Lymphoma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia |
Barbara Ann Karmanos Cancer Institute |
2011-07 | |
| NCT01492881 | WITHDRAWN | Multiple Myeloma |
UNC Lineberger Comprehensive Cancer Center |
2012-04 | PHASE2 |
| NCT01255514 | COMPLETED | Multiple Myeloma |
Yonsei University |
2008-10-30 | PHASE2 |
| NCT01381692 | COMPLETED | Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Small Lymphocytic Lymphoma |
National Cancer Institute (NCI) |
2011-07-20 | PHASE1; PHASE2 |
| NCT01255527 | UNKNOWN | Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation |
Yonsei University |
2010-10 | PHASE1; PHASE2 |
| NCT00861250 | COMPLETED | Multiple Myeloma |
Tampere University Hospital |
2009-03 | PHASE2; PHASE3 |
| NCT01568866 | COMPLETED | Multiple Myeloma |
Amgen |
2012-06-20 | PHASE3 |
| NCT01226849 | COMPLETED | Diffuse Large B-Cell Lymphoma |
Singapore General Hospital |
2010-11 | PHASE1 |
| NCT01460602 | WITHDRAWN | Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma |
Louisiana State University Health Sciences Center Shreveport |
2010-05 | PHASE1; PHASE2 |
| NCT00598169 | COMPLETED | Lymphoma |
AIDS Malignancy Consortium |
2007-11 | PHASE1 |
| NCT01029730 | COMPLETED | Lymphoma |
SCRI Development Innovations, LLC |
2010-03 | PHASE2 |
| NCT00081939 | COMPLETED | Multiple Myeloma |
University of Arkansas |
2004-01 | PHASE2 |
| NCT01521533 | COMPLETED | Multiple Myeloma |
TME Pharma AG |
2012-03 | PHASE2 |
| NCT01034553 | COMPLETED | Refractory Multiple Myeloma |
Mayo Clinic |
2010-02 | PHASE1; PHASE2 |
| NCT00983346 | TERMINATED | Cancer; Myeloma; Multiple Myeloma |
University of Utah |
2009-10 | PHASE2 |
| NCT01504776 | COMPLETED | Mantle Cell Lymphoma |
Anand Jillella |
2011-04 | PHASE1 |
| NCT01602224 | COMPLETED | Multiple Myeloma |
Eli Lilly and Company |
2012-07 | PHASE2 |
| NCT00564200 | COMPLETED | Multiple Myeloma |
PETHEMA Foundation |
2007-11 | PHASE2 |
| NCT01484626 | TERMINATED | Multiple Myeloma |
Loyola University |
2011-05-05 | PHASE1; PHASE2 |
| NCT03402295 | COMPLETED | Multiple Myeloma; Effects of Chemotherapy |
Grupo de Estudos Multicentricos em Onco-Hematologia |
2009-06-15 | PHASE3 |
| NCT01365559 | COMPLETED | Multiple Myeloma |
Oncotherapeutics |
2011-05-02 | PHASE1; PHASE2 |
| NCT01376401 | COMPLETED | Multiple Myeloma |
PETHEMA Foundation |
2011-07 | PHASE2 |
| NCT01478048 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2011-11-30 | PHASE2 |
| NCT01000285 | COMPLETED | Leukemia-Lymphoma, Adult T-Cell |
Washington University School of Medicine |
2010-09 | PHASE1; PHASE2 |
| NCT01127009 | COMPLETED | Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia |
Case Comprehensive Cancer Center |
2010-07 | PHASE1 |
| NCT01053949 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2009-10 | PHASE2 |
| NCT01536067 | TERMINATED | Waldenström Macroglobulinemia |
Roswell Park Cancer Institute |
2012-04 | PHASE2 |
| NCT01315873 | TERMINATED | Multiple Myeloma |
NYU Langone Health |
2011-09 | PHASE2 |
| NCT01537861 | TERMINATED | Multiple Myeloma |
Washington University School of Medicine |
2012-06 | EARLY_PHASE1 |
| NCT01078441 | TERMINATED | Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2010-09 | PHASE2 |
| NCT01083602 | COMPLETED | Relapsed and Bortezomib Refractory Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse |
Novartis Pharmaceuticals |
2010-06 | PHASE2 |
| NCT01125293 | TERMINATED | Waldenstrom's Macroglobulinemia |
Dana-Farber Cancer Institute |
2010-04 | PHASE1; PHASE2 |
| NCT00784823 | COMPLETED | Multiple Myeloma |
Hackensack Meridian Health |
2007-01 | PHASE1; PHASE2 |
| NCT02808091 | TERMINATED | Extranodal NK-T-CELL LYMPHOMA |
National Cancer Centre, Singapore |
2011-03 | PHASE2 |
| NCT01063907 | COMPLETED | Multiple Myeloma |
Kyowa Kirin Co., Ltd. |
2010-03 | PHASE1; PHASE2 |
| NCT01783522 | TERMINATED | Chemotherapeutic Agent Toxicity; Multiple Myeloma; Peripheral Neuropathy |
Beth Faiman |
2013-02 | PHASE2 |
| NCT00711828 | COMPLETED | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Nodal Marginal Zone Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia |
Mayo Clinic |
2008-08 | PHASE2 |
| NCT00532389 | COMPLETED | Multiple Myeloma |
Novartis Pharmaceuticals |
2007-10 | PHASE1 |
| NCT01322776 | UNKNOWN | Mantle Cell Lymphoma Recurrent |
Sun Yat-sen University |
2011-03 | PHASE1; PHASE2 |
| NCT01328236 | UNKNOWN | Plasma Cell Leukemia; Multiple Myeloma |
Clinical Service, China |
2010-09 | PHASE2 |
| NCT00548717 | TERMINATED | Graft-vs-Host Disease |
Dana-Farber Cancer Institute |
2007-10 | PHASE2 |
| NCT02467010 | COMPLETED | Multiple Myeloma |
University Medical Center Groningen |
2008-09 | PHASE2 |
| NCT00714246 | TERMINATED | Non Small Cell Lung Cancer |
Milton S. Hershey Medical Center |
2008-10 | PHASE1 |
| NCT00972959 | COMPLETED | Multiple Myeloma |
University of Athens |
2009-07 | PHASE2 |
| NCT01397591 | TERMINATED | Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma |
OHSU Knight Cancer Institute |
2011-10 | PHASE2 |
| NCT00410423 | COMPLETED | Relapsed Acute Leukemia; Refractory Acute Leukemia |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2006-01 | PHASE1; PHASE2 |
| NCT01633645 | COMPLETED | Non Small Cell Lung Cancer; Metastatic |
University Hospital of Crete |
2009-06 | PHASE2 |
| NCT00108069 | COMPLETED | Glioma |
National Cancer Institute (NCI) |
2005-04 | PHASE2 |
| NCT00507416 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2007-06 | PHASE3 |
| NCT00869323 | TERMINATED | Lymphoproliferative Disorder |
Masonic Cancer Center, University of Minnesota |
2009-03 | PHASE2 |
| NCT01078961 | COMPLETED | Melanoma |
Massachusetts General Hospital |
2010-09 | PHASE1 |
| NCT01323920 | COMPLETED | Leukemia; Lymphoma; Myelodysplastic Syndrome |
Dana-Farber Cancer Institute |
2011-05 | PHASE2 |
| NCT01312818 | TERMINATED | Acute Lymphoblastic Leukemia |
Masonic Cancer Center, University of Minnesota |
2011-06 | PHASE2 |
| NCT00689507 | COMPLETED | Multiple Myeloma |
Applied Molecular Evolution |
2008-03 | PHASE1 |
| NCT00813150 | COMPLETED | Multiple Myeloma |
Janssen-Cilag G.m.b.H |
2009-01 | PHASE3 |
| NCT01171092 | COMPLETED | Malignant Lymphoma, Stem Cell Type; Autologous Transplant |
University of Kansas Medical Center |
2010-09 | EARLY_PHASE1 |
| NCT00084747 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Jonsson Comprehensive Cancer Center |
2004-06 | PHASE1; PHASE2 |
| NCT00376961 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2006-08 | PHASE2 |
| NCT00771875 | COMPLETED | Graft Rejection |
University of Cincinnati |
2008-09 | PHASE2 |
| NCT00691704 | COMPLETED | Multiple Myeloma |
Cristina Gasparetto |
2008-08 | PHASE2 |
| NCT00750815 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2008-09 | PHASE1; PHASE2 |
| NCT00590603 | TERMINATED | Multiple Myeloma |
Duke University |
2008-07 | PHASE1 |
| NCT01078454 | COMPLETED | Light Chain Deposition Disease; Primary Systemic Amyloidosis |
National Cancer Institute (NCI) |
2010-11 | PHASE3 |
| NCT00581776 | COMPLETED | Mantle Cell Lymphoma |
University of Wisconsin, Madison |
2005-05 | PHASE2 |
| NCT00510887 | TERMINATED | Lymphoma, Follicular |
Duke University |
2007-01 | PHASE2 |
| NCT00428545 | COMPLETED | Advanced Malignancy; Lymphoma; Myeloma; Solid Tumors |
M.D. Anderson Cancer Center |
2007-01 | PHASE1 |
| NCT00798720 | COMPLETED | Carcinoma, Non Small Cell Lung |
University of Wisconsin, Madison |
2008-12 | PHASE2 |
| NCT00082784 | COMPLETED | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Nodal Marginal Zone Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Plasma Cell Myeloma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia |
National Cancer Institute (NCI) |
2004-03 | PHASE1 |
| NCT00378209 | COMPLETED | Multiple Myeloma |
Dana-Farber Cancer Institute |
2006-08 | PHASE2 |
| NCT00839956 | COMPLETED | DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma |
Fred Hutchinson Cancer Center |
2009-02 | PHASE2 |
| NCT01164709 | COMPLETED | Leukemia; Lymphoma; Mature T-cell and Nk-cell Neoplasms; Multiple Myeloma and Plasma Cell Neoplasm |
Swiss Cancer Institute |
2010-07 | PHASE1 |
| NCT00644696 | COMPLETED | Neuroblastoma |
University of Michigan Rogel Cancer Center |
2008-04 | PHASE1 |
| NCT00439361 | COMPLETED | Hodgkin Lymphoma; Lymphoma |
M.D. Anderson Cancer Center |
2007-02 | PHASE1 |
| NCT01249690 | UNKNOWN | Multiple Myeloma |
Second Military Medical University |
2010-06 | PHASE4 |
| NCT00383474 | COMPLETED | Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With Minimal Differentiation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Adult Erythroleukemia; Adult Pure Erythroid Leukemia; Blastic Phase; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Disease; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2006-08 | PHASE1 |
| NCT00884546 | COMPLETED | Advanced Cancer, Various, NOS |
Bristol-Myers Squibb |
2009-07 | PHASE1 |
| NCT00307086 | COMPLETED | Multiple Myeloma; Plasma Cell Leukemia |
H. Lee Moffitt Cancer Center and Research Institute |
2005-06 | PHASE2 |
| NCT00815919 | COMPLETED | Chronic Graft Versus Host Disease |
Dana-Farber Cancer Institute |
2008-12 | PHASE2 |
| NCT00544284 | COMPLETED | Brain and Central Nervous System Tumors; Lymphoma; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
City of Hope Medical Center |
2005-01 | PHASE1 |
| NCT00744354 | TERMINATED | Multiple Myeloma and Plasma Cell Neoplasm |
UNC Lineberger Comprehensive Cancer Center |
2008-10 | PHASE1 |
| NCT00515138 | TERMINATED | Lymphoma, B-Cell |
University of California, San Francisco |
2007-05 | EARLY_PHASE1 |
| NCT00103259 | COMPLETED | Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer |
National Cancer Institute (NCI) |
2005-07 | PHASE2 |
| NCT02353468 | TERMINATED | Refractory Plasma Cell Myeloma |
University of Colorado, Denver |
2009-12 | PHASE2 |
| NCT00718601 | COMPLETED | Multiple Myeloma |
Geron Corporation |
2008-07 | PHASE1 |
| NCT00773747 | COMPLETED | Multiple Myeloma |
Merck Sharp & Dohme LLC |
2008-12-01 | PHASE3 |
| NCT01055301 | WITHDRAWN | Multiple Myeloma; Plasma Cell Myeloma |
SWOG Cancer Research Network |
2011-07 | PHASE2 |
| NCT01300793 | TERMINATED | Non-Hodgkin's Lymphoma; B-cell Lymphoma |
University of California, San Francisco |
2007-05 | PHASE1 |
| NCT00920855 | COMPLETED | Multiple Myeloma |
Cephalon |
2009-06 | PHASE1; PHASE2 |
| NCT00538187 | TERMINATED | Adult Non-Hodgkin Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma |
National Cancer Institute (NCI) |
2007-12 | PHASE1 |
| NCT00458705 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Memorial Sloan Kettering Cancer Center |
2006-11 | PHASE2 |
| NCT01072773 | COMPLETED | Primary Systemic Amyloidosis |
Mayo Clinic |
2010-03 | PHASE2 |
| NCT00872521 | COMPLETED | Multiple Myeloma |
Janssen-Cilag Pty Ltd |
2009-01 | PHASE2 |
| NCT00366106 | TERMINATED | Multiple Myeloma |
Accelerated Community Oncology Research Network |
2006-07 | PHASE2 |
| NCT00440726 | COMPLETED | Acute Lymphoblastic Leukemia |
Therapeutic Advances in Childhood Leukemia Consortium |
2006-08-04 | PHASE1; PHASE2 |
| NCT00290706 | TERMINATED | Lymphoma |
Northwestern University |
2006-04-07 | PHASE1; PHASE2 |
| NCT00560352 | TERMINATED | Multiple Myeloma |
Bristol-Myers Squibb |
2008-02 | PHASE1 |
| NCT00148317 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2005-06 | PHASE2 |
| NCT00483262 | COMPLETED | Multiple Myeloma |
Dana-Farber Cancer Institute |
2007-05 | PHASE1; PHASE2 |
| NCT00581919 | COMPLETED | Multiple Myeloma |
University of Wisconsin, Madison |
2004-02 | PHASE2 |
| NCT00772668 | TERMINATED | Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma |
University of Miami |
2009-09-25 | |
| NCT00288028 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Barbara Ann Karmanos Cancer Institute |
2005-07 | PHASE1 |
| NCT00287872 | COMPLETED | Multiple Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2004-09 | PHASE2 |
| NCT00262873 | COMPLETED | Myelodysplastic Syndromes |
University of Rochester |
2005-05 | PHASE2 |
| NCT00315757 | COMPLETED | Multiple Myeloma |
Human Genome Sciences Inc. |
2006-05 | PHASE2 |
| NCT01462773 | COMPLETED | Melanoma |
Ohio State University Comprehensive Cancer Center |
2006-01 | PHASE1 |
| NCT00507442 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2007-08 | PHASE1; PHASE2 |
| NCT00520767 | COMPLETED | Primary Systemic Amyloidosis; Light Chain Deposition Disease |
Barbara Ann Karmanos Cancer Institute |
2007-09 | PHASE2 |
| NCT01445405 | COMPLETED | Carcinoma, Squamous; Head and Neck Cancer; Oral Cancer; Laryngeal Cancer; Pharyngeal Cancer |
National Cancer Institute (NCI) |
2008-02-05 | PHASE1 |
| NCT00411905 | COMPLETED | Myelodysplastic Syndromes |
Groupe Francophone des Myelodysplasies |
2006-06-01 | PHASE1; PHASE2 |
| NCT00369226 | COMPLETED | Hematologic Malignancies |
Dana-Farber Cancer Institute |
2006-08 | PHASE1; PHASE2 |
| NCT00742404 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Oncotherapeutics |
2008-07 | PHASE2 |
| NCT00641706 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor |
National Cancer Institute (NCI) |
2008-07 | PHASE2 |
| NCT00791011 | COMPLETED | Hodgkin's Lymphoma; Low Grade Lymphoma; Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin's Lymphoma; Diffuse Large Cell Lymphoma |
Amgen |
2008-02 | PHASE1 |
| NCT00093704 | TERMINATED | Lymphoma; Lymphoproliferative Disorder |
Jonsson Comprehensive Cancer Center |
2005-03 | PHASE1 |
| NCT00362882 | COMPLETED | Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2006-07 | PHASE2 |
| NCT00720148 | COMPLETED | Solid Tumors |
Emory University |
2008-02 | PHASE1 |
| NCT00372905 | TERMINATED | Lymphoma |
Northwestern University |
2007-07-24 | PHASE1; PHASE2 |
| NCT00329589 | COMPLETED | Brain Cancer; Head and Neck Cancer; Cervix Cancer; Central Nervous System Neoplasms |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2005-09 | PHASE1 |
| NCT00312845 | COMPLETED | Non-Hodgkin's Lymphoma |
Millennium Pharmaceuticals, Inc. |
2006-03 | PHASE3 |
| NCT00104871 | COMPLETED | Insular Thyroid Cancer; Recurrent Thyroid Cancer; Stage II Follicular Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Papillary Thyroid Cancer |
National Cancer Institute (NCI) |
2004-12 | PHASE2 |
| NCT00303797 | COMPLETED | Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Stage III Multiple Myeloma; Stage IV Chronic Lymphocytic Leukemia; Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2005-12 | PHASE1 |
| NCT00723658 | WITHDRAWN | Lymphoma |
SWOG Cancer Research Network |
2008-09 | PHASE2 |
| NCT00458913 | COMPLETED | Malignant Mesothelioma |
European Organisation for Research and Treatment of Cancer - EORTC |
2007-02 | PHASE2 |
| NCT00151320 | COMPLETED | Non-Hodgkin's Lymphoma |
Weill Medical College of Cornell University |
2004-01 | PHASE1; PHASE2 |
| NCT00546780 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2008-02 | PHASE3 |
| NCT00608907 | COMPLETED | Multiple Myeloma; Non-Hodgkin's Lymphoma |
Millennium Pharmaceuticals, Inc. |
2007-09 | PHASE1 |
| NCT00096005 | TERMINATED | Adult Grade III Lymphomatoid Granulomatosis; AIDS-related Peripheral/Systemic Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia |
National Cancer Institute (NCI) |
2004-11 | PHASE1 |
| NCT00536575 | COMPLETED | Multiple Myeloma |
SCRI Development Innovations, LLC |
2007-11 | PHASE1; PHASE2 |
| NCT00348985 | COMPLETED | Adult Grade III Lymphomatoid Granulomatosis; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia |
National Cancer Institute (NCI) |
2006-03 | PHASE1 |
| NCT00023712 | COMPLETED | Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer |
National Cancer Institute (NCI) |
2001-11-05 | PHASE2 |
| NCT00061932 | COMPLETED | Adenocarcinoma of the Gastroesophageal Junction; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage IIIB Gastric Cancer; Stage IIIC Gastric Cancer; Stage IV Gastric Cancer |
National Cancer Institute (NCI) |
2003-04 | PHASE2 |
| NCT00389701 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Sparrow Regional Cancer Center |
2006-03 | PHASE2 |
| NCT00513877 | COMPLETED | Malignant Mesothelioma |
Cancer Trials Ireland |
2006-05 | PHASE2 |
| NCT00718640 | TERMINATED | Multiple Myeloma |
Janssen-Ortho Inc., Canada |
2007-10 | PHASE2 |
| NCT00473590 | COMPLETED | Multiple Myeloma |
Genentech, Inc. |
2007-06 | PHASE2 |
| NCT00793650 | TERMINATED | Cancer; Multiple Myeloma |
Emory University |
2005-05 | PHASE1; PHASE2 |
| NCT00054483 | COMPLETED | Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia |
National Cancer Institute (NCI) |
2003-01 | PHASE1 |
| NCT00611325 | COMPLETED | Glioblastoma; Gliosarcoma |
Duke University |
2008-05 | PHASE2 |
| NCT00374699 | COMPLETED | Peripheral T-Cell Lymphomas; Non-Hodgkin Lymphoma |
Samsung Medical Center |
2006-04 | PHASE1; PHASE2 |
| NCT00622674 | COMPLETED | Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Pancreatic Cancer; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific |
Masonic Cancer Center, University of Minnesota |
2005-11 | PHASE1 |
| NCT00276614 | COMPLETED | Kidney Cancer |
Jonsson Comprehensive Cancer Center |
2006-04 | PHASE2 |
| NCT00547534 | COMPLETED | Non-Hodgkin's Lymphoma |
University of Rochester |
2007-10 | PHASE2 |
| NCT00833560 | COMPLETED | Multiple Myeloma |
Janssen-Cilag G.m.b.H |
2006-03 | PHASE2 |
| NCT00814541 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Cancer Trials Ireland |
2005-12 | PHASE2 |
| NCT00508209 | UNKNOWN | Multiple Myeloma |
Nordic Myeloma Study Group |
2007-07 | PHASE2 |
| NCT00201877 | COMPLETED | Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma |
Ohio State University Comprehensive Cancer Center |
2004-12 | PHASE2 |
| NCT00417911 | COMPLETED | Multiple Myeloma |
Nordic Myeloma Study Group |
2005-12 | PHASE3 |
| NCT00609817 | TERMINATED | Multiple Myeloma |
La Jolla Pharmaceutical Company |
2008-05 | PHASE1 |
| NCT00577668 | WITHDRAWN | Multiple Myeloma |
University of Arkansas |
2007-04 | PHASE2 |
| NCT00531453 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2007-10 | PHASE2 |
| NCT00407303 | COMPLETED | Mantle-Cell Lymphoma |
Gemin X |
2006-10 | PHASE1; PHASE2 |
| NCT00514371 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2007-08 | PHASE2; PHASE3 |
| NCT00426855 | COMPLETED | Lymphoma, Non-Hodgkin |
Peter Moosmann |
2007-01 | PHASE1; PHASE2 |
| NCT00030368 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2001-11 | PHASE1 |
| NCT00464178 | TERMINATED | Multiple Myeloma |
Hackensack Meridian Health |
2007-04 | PHASE2 |
| NCT00657553 | TERMINATED | Multiple Myeloma |
University of Arkansas |
2008-02 | PHASE3 |
| NCT00609167 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Mayo Clinic |
2006-12 | PHASE2 |
| NCT00789256 | COMPLETED | Acute Myelogenous Leukemia; Myelodysplastic Syndromes |
Dartmouth-Hitchcock Medical Center |
2004-09 | |
| NCT00437086 | COMPLETED | Chronic Myeloproliferative Disorders; Leukemia |
Mayo Clinic |
2005-09 | EARLY_PHASE1 |
| NCT00280176 | COMPLETED | Colorectal Cancer |
UNC Lineberger Comprehensive Cancer Center |
2003-04 | PHASE1 |
| NCT00985907 | TERMINATED | Multiple Myeloma; Patient Participation |
University of California, San Francisco |
2004-10-28 | PHASE1; PHASE2 |
| NCT00382954 | COMPLETED | Acute Myelogenous Leukemia |
University of Kentucky |
2004-02 | PHASE1 |
| NCT00352742 | TERMINATED | Multiple Myeloma |
Attenuon |
2006-06 | PHASE1; PHASE2 |
| NCT00408928 | COMPLETED | Graft-versus-Host Disease |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2005-11 | PHASE2 |
| NCT00479167 | TERMINATED | Follicular Lymphoma |
Rush University Medical Center |
2007-05 | PHASE2 |
| NCT00085410 | TERMINATED | Adenocarcinoma of the Extrahepatic Bile Duct; Adenocarcinoma of the Gallbladder; Advanced Adult Primary Liver Cancer; Gastrointestinal Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer |
National Cancer Institute (NCI) |
2004-01 | PHASE2 |
| NCT00573391 | TERMINATED | Multiple Myeloma |
University of Arkansas |
2006-08 | PHASE3 |
| NCT00316940 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Oncotherapeutics |
2005-12 | PHASE1 |
| NCT00124579 | TERMINATED | Multiple Myeloma |
SWOG Cancer Research Network |
2005-08 | PHASE2 |
| NCT00636311 | COMPLETED | Hodgkin Disease |
Istituto Clinico Humanitas |
2008-02 | PHASE2 |
| NCT01801436 | COMPLETED | Multiple Myeloma |
Johnson & Johnson Taiwan Ltd |
2006-12 | PHASE3 |
| NCT00511069 | COMPLETED | Leukemia |
University of Bologna |
2006-07 | PHASE2 |
| NCT00734149 | COMPLETED | Multiple Myeloma |
Duke University |
2004-07 | PHASE2 |
| NCT00478075 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Mayo Clinic |
2005-09 | PHASE1; PHASE2 |
| NCT00388089 | COMPLETED | Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
University of California, Davis |
2004-12 | PHASE1 |
| NCT00509379 | COMPLETED | Lymphoma; Non-Hodgkin Lymphoma |
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie |
2006-09 | PHASE2 |
| NCT00052689 | COMPLETED | Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2002-12 | PHASE2 |
| NCT01902862 | TERMINATED | Lymphoma, Follicular |
Janssen-Cilag G.m.b.H |
2006-02 | PHASE2 |
| NCT00504634 | COMPLETED | Multiple Myeloma |
M.D. Anderson Cancer Center |
2004-01 | PHASE2 |
| NCT00075751 | COMPLETED | Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2004-01 | PHASE2 |
| NCT00291538 | COMPLETED | Multiple Myeloma |
Nantes University Hospital |
2006-02 | PHASE1 |
| NCT00117351 | TERMINATED | Carcinoma, Non-Small-Cell Lung; Adenocarcinoma, Bronchiolo-Alveolar |
Millennium Pharmaceuticals, Inc. |
2005-04 | PHASE2 |
| NCT00006773 | TERMINATED | Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor |
National Cancer Institute (NCI) |
2001-05 | PHASE1 |
| NCT00346645 | TERMINATED | STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER |
Gustave Roussy, Cancer Campus, Grand Paris |
2006-06 | PHASE2 |
| NCT00411593 | WITHDRAWN | Lung Cancer |
M.D. Anderson Cancer Center |
2006-11 | PHASE1; PHASE2 |
| NCT00561743 | COMPLETED | Multiple Myeloma |
Janssen-Ortho Inc., Canada |
2005-11 | PHASE2 |
| NCT00059618 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
M.D. Anderson Cancer Center |
2003-04 | PHASE1 |
| NCT00082966 | COMPLETED | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma |
National Cancer Institute (NCI) |
2004-03 | PHASE2 |
| NCT00250926 | COMPLETED | Waldenstrom's Macroglobulinemia |
Dana-Farber Cancer Institute |
2005-10 | PHASE2 |
| NCT00257114 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
PHASE4 | |
| NCT00098982 | COMPLETED | Colorectal Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2004-09 | PHASE1 |
| NCT00389805 | COMPLETED | Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
University of California, Davis |
2005-03 | PHASE1; PHASE2 |
| NCT00129207 | COMPLETED | Tumors |
Millennium Pharmaceuticals, Inc. |
PHASE1 | |
| NCT00085696 | COMPLETED | B-Cell Lymphoma; Follicular Lymphoma; Marginal Lymphoma |
Millennium Pharmaceuticals, Inc. |
2004-05 | PHASE2 |
| NCT00028587 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2001-12 | PHASE1 |
| NCT00040768 | TERMINATED | Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-04 | PHASE2 |
| NCT00077467 | COMPLETED | Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Promyelocytic Leukemia (M3); Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2004-01 | PHASE1 |
| NCT00045695 | COMPLETED | Lymphoma |
NCIC Clinical Trials Group |
2002-08 | PHASE2 |
| NCT00068484 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2003-07 | PHASE1 |
| NCT00093028 | COMPLETED | Multiple Myeloma |
University of Arkansas |
2004-01 | PHASE3 |
| NCT00021216 | COMPLETED | Unspecified Childhood Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2001-11 | PHASE1 |
| NCT00193232 | COMPLETED | Prostate Cancer |
SCRI Development Innovations, LLC |
2004-05 | PHASE2 |
| NCT00103103 | TERMINATED | Gastric Cancer |
California Cancer Consortium |
2005-03 | PHASE2 |
| NCT00030875 | COMPLETED | Lymphoma |
NCIC Clinical Trials Group |
2002-11-19 | PHASE2 |
| NCT00066508 | COMPLETED | Lymphoma |
Jonsson Comprehensive Cancer Center |
2003-05 | PHASE2 |
| NCT00063726 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2002-04 | PHASE3 |
| NCT00023881 | TERMINATED | Leukemia |
M.D. Anderson Cancer Center |
2001-07-02 | PHASE2 |
| NCT00064610 | COMPLETED | Prostatic Neoplasms |
Millennium Pharmaceuticals, Inc. |
2002-12 | PHASE1; PHASE2 |
| NCT00051974 | COMPLETED | Non-Small Cell Lung Cancer |
Millennium Pharmaceuticals, Inc. |
2002-12 | PHASE2 |
| NCT00025584 | COMPLETED | Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2001-08 | PHASE2 |
| NCT00064012 | COMPLETED | Lung Cancer |
University of Wisconsin, Madison |
2003-05 | PHASE2 |
| NCT00027716 | COMPLETED | Sarcoma |
Memorial Sloan Kettering Cancer Center |
2001-10 | PHASE2 |
| NCT00052338 | COMPLETED | Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-09 | PHASE1 |
| NCT00017329 | COMPLETED | Kidney Cancer |
Memorial Sloan Kettering Cancer Center |
2001-04 | PHASE2 |
| NCT00023855 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
University of Wisconsin, Madison |
2001-06 | PHASE1 |
| NCT00006098 | COMPLETED | Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes |
Memorial Sloan Kettering Cancer Center |
2000-04 | PHASE1 |
| NCT00004002 | COMPLETED | Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
NYU Langone Health |
1999-07 | PHASE1 |
| NCT00261612 | UNKNOWN | Lymphoma, Mantle-Cell |
Medical University of Vienna |
2005-01 | PHASE2 |
| NCT00358020 | COMPLETED | Multiple Myeloma |
University of Turin, Italy |
2004-11 | PHASE2 |
| NCT00265928 | TERMINATED | Lymphoma |
University of Virginia |
PHASE2 | |
| NCT00095680 | COMPLETED | Multiple Myeloma |
Scios, Inc. |
2004-11 | PHASE2 |
| NCT00148018 | TERMINATED | Hodgkin Disease |
University of Cologne |
2005-03 | PHASE2 |
| NCT00068289 | COMPLETED | Lung Cancer |
SWOG Cancer Research Network |
2003-09 | PHASE2 |
| NCT00373906 | COMPLETED | MALT Lymphoma |
Medical University of Vienna |
PHASE2 | |
| NCT00216697 | COMPLETED | Multiple Myeloma |
Janssen Pharmaceutical K.K. |
2005-03 | PHASE2 |
| NCT00217503 | COMPLETED | Lymphoma |
National Cancer Institute (NCI) |
2005-07 | PHASE2 |
| NCT00995059 | WITHDRAWN | Multiple Myeloma; Refractory Multiple Myeloma |
Mayo Clinic |
PHASE1; PHASE2 | |
| NCT00028912 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Memorial Sloan Kettering Cancer Center |
2001-11 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-06-18)
Check the
Bortezomib
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Bortezomib Mechanism of Action: 20S Proteasome Inhibition in Plasma Cell Research
- Bortezomib: Selectivity & Specificity
- Bortezomib Working Concentration | Cell Culture | Treatment
- Bortezomib Solubility in DMSO
- Bortezomib Storage
- Bortezomib Stability
- Bortezomib Combination Database
- Bortezomib Molecular Weight
- Bortezomib SMILES
- Bortezomib CAS Number
- Bortezomib Chemical Structure (2D and 3D)
- Bortezomib IC50 for Cell-based and Cell-free Assays
- Bortezomib Sigma (539142)? Try a better option.
- Bortezomib MedChemExpress (HY-10227)? Try a better option.
- Bortezomib Cayman (10008822)? Try a better option.
- Bortezomib APExBIO (A2614)? Try a better option.
- Bortezomib SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.